BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 3132928)

  • 1. Pharmacology of the dual inhibitor of cyclooxygenase and 5-lipoxygenase 3-hydroxy-5-trifluoromethyl-N-(2-(2-thienyl)-2-phenyl-ethenyl)-benzo (b)thiophene-2-carboxamide.
    Bailey PJ; Dallob AL; Allison DL; Anderson RL; Bach T; Durette PL; Hand KM; Hopple SL; Luell S; Meurer R
    Arzneimittelforschung; 1988 Mar; 38(3):372-8. PubMed ID: 3132928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-652,343: a novel dual 5-lipoxygenase/cyclooxygenase inhibitor.
    Tischler A; Bailey P; Dallob A; Witzel B; Durette P; Rupprecht K; Allison D; Dougherty H; Humes J; Ham E
    Adv Prostaglandin Thromboxane Leukot Res; 1986; 16():63-6. PubMed ID: 2949565
    [No Abstract]   [Full Text] [Related]  

  • 3. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.
    Argentieri DC; Ritchie DM; Ferro MP; Kirchner T; Wachter MP; Anderson DW; Rosenthale ME; Capetola RJ
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1399-408. PubMed ID: 7996452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. General pharmacology of the butanamide derivative S 19812, a new dual inhibitor of cyclooxygenase and lipoxygenase pathways.
    Tordjman C; Andre N; Bresson Y; Bellot I; Deschamps C; Pastoureau P; Wierzbicki M
    Arzneimittelforschung; 2003; 53(12):844-9. PubMed ID: 14732965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological profile of SK&F 105809, a dual inhibitor of arachidonic acid metabolism.
    Hanna N; Marshall PJ; Newton J; Schwartz L; Kirsh R; Dimartino MJ; Adams J; Bender P; Griswold DE
    Drugs Exp Clin Res; 1990; 16(4):137-47. PubMed ID: 2127565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
    J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacological profile of 2-(8-methyl-10,11-dihydro-11-oxodibenz[b,f]oxepin-2-yl)propionic acid (AD-1590), a new non-steroidal anti-inflammatory agent with potent antipyretic activity.
    Nakamura H; Yokoyama Y; Motoyoshi S; Ishii K; Imazu C; Seto Y; Kadokawa T; Shimizu M
    Arzneimittelforschung; 1983; 33(11):1555-69. PubMed ID: 6607053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arachidonic acid-induced pleurisy (ARIP): an in vivo model for testing 5-lipoxygenase inhibition.
    Boctor AM; Burke C; Hovinga ME
    Methods Find Exp Clin Pharmacol; 1987 Dec; 9(12):793-7. PubMed ID: 2831442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological evaluation of 2-(4-amino-phenyl)-3-(3,5-dihydroxylphenyl) propenoic acid.
    Xu GL; Liu F; Zhao Y; Ao GZ; Xi L; Ju M; Xue T
    Basic Clin Pharmacol Toxicol; 2009 Nov; 105(5):350-6. PubMed ID: 19744157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation.
    Kirchner T; Argentieri DC; Barbone AG; Singer M; Steber M; Ansell J; Beers SA; Wachter MP; Wu W; Malloy E; Stewart A; Ritchie DM
    J Pharmacol Exp Ther; 1997 Aug; 282(2):1094-101. PubMed ID: 9262379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of the potent new non-steroidal anti-inflammatory agent aceclofenac.
    Grau M; Guasch J; Montero JL; Felipe A; Carrasco E; Juliá S
    Arzneimittelforschung; 1991 Dec; 41(12):1265-76. PubMed ID: 1815528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A sulphonamido-indanone derivative CGP 28237 (ZK 34228), a novel non-steroidal anti-inflammatory agent without gastro-intestinal ulcerogenicity in rats.
    Böttcher I; Schweizer A; Glatt M; Werner H
    Drugs Exp Clin Res; 1987; 13(5):237-45. PubMed ID: 3500026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of novel anti-inflammatory compounds on healing of acetic acid-induced gastric ulcer in rats.
    Lesch CA; Gilbertsen RB; Song Y; Dyer RD; Schrier D; Kraus ER; Sanchez B; Guglietta A
    J Pharmacol Exp Ther; 1998 Oct; 287(1):301-6. PubMed ID: 9765350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of a novel class of rofecoxib analogues as dual inhibitors of cyclooxygenases (COXs) and lipoxygenases (LOXs).
    Chen QH; Rao PN; Knaus EE
    Bioorg Med Chem; 2006 Dec; 14(23):7898-909. PubMed ID: 16904331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The in vitro 5-lipoxygenase and cyclo-oxygenase inhibitor L-652,343 does not inhibit 5-lipoxygenase in vivo in human skin.
    Barr RM; Black AK; Dowd PM; Koro O; Mistry K; Isaacs JL; Greaves MW
    Br J Clin Pharmacol; 1988 Jan; 25(1):23-6. PubMed ID: 2835975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics.
    Müller-Peddinghaus R; Kohlsdorfer C; Theisen-Popp P; Fruchtmann R; Perzborn E; Beckermann B; Bühner K; Ahr HJ; Mohrs KH
    J Pharmacol Exp Ther; 1993 Oct; 267(1):51-7. PubMed ID: 8229782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological studies of a new non-steroidal antiinflammatory drug: 2-(5-ethylpyridin-2-yl)benzimidazole (KB-1043).
    Ito K; Kagaya H; Fukuda T; Yoshino K; Nose T
    Arzneimittelforschung; 1982; 32(1):49-55. PubMed ID: 6977364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach.
    Chan CC; Boyce S; Brideau C; Ford-Hutchinson AW; Gordon R; Guay D; Hill RG; Li CS; Mancini J; Penneton M
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1531-7. PubMed ID: 7562530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-[3-(1,1-Dimethylethyl)-5-methoxyphenyloxazolo[4,5-b]pyridine, a new topical antiinflammatory and analgesic compound lacking systemic activity and gastric side effects.
    Bonney RJ; Olson BJ; Bach T; Beveridge G; Goldenberg MM; Gitterman CO; Humes JL; Lu AY; Hucker H; Dougherty H
    Arzneimittelforschung; 1985; 35(4):715-20. PubMed ID: 3874629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.